Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

被引：0

作者：

Santoro, Armando ^{[1
,2
]}

Johnson, Nathalie A. ^{[3
]}

Savage, Kerry J. ^{[4
]}

Avigdor, Abraham ^{[5
]}

Bazargan, Ali ^{[6
,7
]}

Borchmann, Peter ^{[8
]}

Gasiorowski, Robin ^{[9
]}

Gregory, Gareth P. ^{[10
]}

Herishanu, Yair ^{[11
]}

Madan, Sumit ^{[12
]}

Minuk, Leonard ^{[13
,14
]}

Musuraca, Gerardo ^{[15
]}

West, Rachel Marceau ^{[16
]}

Pillai, Pallavi ^{[16
]}

Marinello, Patricia ^{[16
]}

Zinzani, Pier Luigi ^{[17
,18
]}

机构：

[1] Humanitas Univ, Pieve Emanuele, Milan, Italy

[2] IRCCS Humanitas Res Hosp Humanitas Canc Ctr Rozza, Milan, Italy

[3] Jewish Gen Hosp, Montreal, PQ, Canada

[4] BC Canc, Div Med Oncol, Vancouver, BC, Canada

[5] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[6] Univ Melbourne, Melbourne, Vic, Australia

[7] St Vincents Hosp, Fitzroy, Vic, Australia

[8] Univ Hosp Cologne, Cologne, Germany

[9] Univ Sydney, Concord Hosp, Concord, NSW, Australia

[10] Monash Univ, Sch Clin Sci Monash Hlth, Melbourne, Vic, Australia

[11] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[12] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[13] CancerCare Manitoba, Winnipeg, MB, Canada

[14] Univ Manitoba, Winnipeg, MB, Canada

[15] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Meldola, Italy

[16] Merck & Co Inc, Rahway, NJ USA

[17] Univ Bologna Ist Ematol Seragnoli, IRCCS Azienda Osped, Bologna, Italy

[18] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182536

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoyle, Margaret
Paccagnella, Luisa
BLOOD, 2023, 142
[32] Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B-cell lymphoma.
Landsburg, Daniel Jeffrey
Kelly, Kevin
Viner, Jaye
Wang, Jing
Gong, Lucy
Clancy, Myles Steven
Ma, Anna W.
Oki, Yasuhiro
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[33] Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations
Landsburg, Daniel J.
Ramchandren, Radhakrishnan
Hafeez, Amir
Gharavi, Robert
Chander, Tania
Ma, Anna
Burch, Micah M.
Oki, Yasuhiro
BLOOD, 2016, 128 (22)
[34] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
Terui, Yasuhito
Rai, Shinya
Izutsu, Koji
Yamaguchi, Motoko
Takizawa, Jun
Kuroda, Junya
Ishikawa, Takayuki
Kato, Koji
Suehiro, Youko
Fukuhara, Noriko
Ohmine, Ken
Goto, Hideki
Yamamoto, Kazuhito
Kanemura, Nobuhiro
Ueda, Yasunori
Ishizawa, Kenichi
Kumagai, Kyoya
Kawasaki, Atsuko
Saito, Tomohisa
Hashizume, Misato
Shibayama, Hirohiko
CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
[35] Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study
Timmerman, John
Lavie, David
Johnson, Nathalie A.
Avigdor, Abraham
Borchmann, Peter
Andreadis, Charalambos
Bazargan, Ali
Gregory, Gareth P.
Keane, Colm
Tzoran, Inna
Vucinic, Vladan
Zinzani, Pier Luigi
West, Rachel Marceau
Pillai, Pallavi
Marinello, Patricia
Herrera, Alex F.
BLOOD, 2023, 142
[36] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ohmachi, Ken
Niitsu, Nozomi
Uchida, Toshiki
Kim, Seok Jin
Ando, Kiyoshi
Takahashi, Naoki
Takahashi, Naoto
Uike, Naokuni
Eom, Hyeon Seok
Chae, Yee Soo
Terauchi, Takashi
Tateishi, Ukihide
Tatsumi, Mitsuaki
Kim, Won Seog
Tobinai, Kensei
Suh, Cheolwon
Ogura, Michinori
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
[37] A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Flinn, Ian W.
Bartlett, Nancy L.
Blum, Kristie A.
Ardeshna, Kirit M.
LaCasce, Ann S.
Flowers, Christopher R.
Shustov, Andrei R.
Thress, Kenneth S.
Mitchell, Patrick
Zheng, Fred
Skolnik, Jeffrey M.
Friedberg, Jonathan W.
EUROPEAN JOURNAL OF CANCER, 2016, 54 : 11 - 17
[38] A Phase ll Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Flinn, Ian
Bartlett, Nancy L.
Blum, Kristie A.
Ardeshna, Kirit M.
LaCasce, Ann
Flowers, Christopher R.
Shustov, Andrei R.
Thress, Kenneth
Zheng, Fred
Skolnik, Jeffery
Friedberg, Jonathan W.
BLOOD, 2014, 124 (21)
[39] Subcutaneous Epcoritamab Versus Standard of Care in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase 3 EPCORE DLBCL-1 Trial
Fox, Christopher P.
Roost, Clausen Michael
Pieternella, Lugtenburg
Balari, Anna S.
Zinzani, Pier L.
Jun, Wu
Laura, Finn
Vindelov, Signe D.
Catherine, Thieblemont
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S32 - S33
[40] Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
Abramson, Jeremy S.
Ku, Matthew
Hertzberg, Mark
Huang, Hui-Qiang
Fox, Christopher P.
Zhang, Huilai
Yoon, Dok Hyun
Kim, Won-Seog
Abdulhaq, Haifaa
Townsend, William
Herbaux, Charles
Zaucha, Jan M.
Zhang, Qing-Yuan
Chang, Hung
Liu, Yanyan
Cheah, Chan Yoon
Ghesquieres, Herve
Simko, Stephen
Orellana-Noia, Victor
Ta, Richard
Relf, James
Dixon, Mark
Kallemeijn, Martine
Mulvihill, Estefania
Huang, Huang
Lundberg, Linda
Gregory, Gareth P.
LANCET, 2024, 404 (10466): : 1940 - 1954

← 1 2 3 4 5 →